Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

Although stimulator of interferon genes (STING) agonists has shown great promise in preclinical studies, the clinical development of STING agonist therapy is challenged by its limited systemic delivery. Here, positively charged fusogenic liposomes loaded with a STING agonist (PoSTING) are designed for systemic delivery and to preferentially target the tumor microenvironment. When PoSTING is administered intravenously, it selectively targets not only tumor cells but also immune and tumor endothelial cells (ECs). In particular, delivery of STING agonists to tumor ECs normalizes abnormal tumor vasculatures, induces intratumoral STING activation, and elicits robust anti-tumor T cell immunity within the tumor microenvironment. Therefore, PoSTING can be used as a systemic delivery platform to overcome the limitations of using STING agonists in clinical trials.

[1]  Shaojie Jiang,et al.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 , 2022, Journal of Hematology & Oncology.

[2]  Bao-Hui Cheng,et al.  Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy , 2022, Molecules.

[3]  D. Irvine,et al.  STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity , 2022, Nature Materials.

[4]  Deanna A. Mele,et al.  Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[5]  T. Dzieciątkowski,et al.  Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment , 2022, International journal of molecular sciences.

[6]  C. Sung,et al.  Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer , 2022, Cancer research and treatment.

[7]  Kyung Soo Park,et al.  Amplifying STING Activation by Cyclic Dinucleotide-Manganese Particles for Local and Systemic Cancer Metalloimmunotherapy , 2021, Nature Nanotechnology.

[8]  Zhishen Ge,et al.  Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy. , 2021, Macromolecular bioscience.

[9]  Yu Seong Lee,et al.  STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer , 2021, Journal for ImmunoTherapy of Cancer.

[10]  J. Luke,et al.  STING Agonists as Cancer Therapeutics , 2021, Cancers.

[11]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[12]  J. Balko,et al.  Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Rohini Sharma,et al.  Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy , 2020, Journal of clinical medicine.

[14]  W. Lee,et al.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.

[15]  Chunyan Liu,et al.  Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy , 2020, Molecular therapy. Methods & clinical development.

[16]  C. Robert.  A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[17]  Zhijian J. Chen,et al.  Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway. , 2020, Immunity.

[18]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[19]  Caicun Zhou,et al.  cGAS-STING, an important pathway in cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[20]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[21]  T. Zheng,et al.  STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.

[22]  K. Valerie,et al.  STING activation in cancer immunotherapy , 2019, Theranostics.

[23]  K. Fitzgerald,et al.  DNA sensing by the cGAS–STING pathway in health and disease , 2019, Nature Reviews Genetics.

[24]  J. Luke,et al.  STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.

[25]  K. Hargadon,et al.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.

[26]  E. Ruoslahti,et al.  Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus , 2018, Nature Communications.

[27]  E. Janssen,et al.  STING, DCs and the link between innate and adaptive tumor immunity , 2017, Molecular immunology.

[28]  Ulrich Kubitscheck,et al.  Fusogenic Liposomes as Nanocarriers for the Delivery of Intracellular Proteins. , 2017, Langmuir : the ACS journal of surfaces and colloids.

[29]  Doheon Lee,et al.  Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. , 2016, Cancer cell.

[30]  Pengyuan Yang,et al.  Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes , 2016, Theranostics.

[31]  Hamidreza Ghandehari,et al.  Nanoparticle Uptake: The Phagocyte Problem. , 2015, Nano today.

[32]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[33]  Leone Spiccia,et al.  Zwitterionic-coated "stealth" nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. , 2014, Small.

[34]  M. Piccart,et al.  A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  G. Barber.  STING-dependent cytosolic DNA sensing pathways. , 2014, Trends in immunology.

[36]  Doheon Lee,et al.  Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. , 2014, Cancer cell.

[37]  Giulio Caracciolo,et al.  Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles , 2013, Journal of Nanoparticle Research.

[38]  D. Jäger,et al.  Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[40]  T. Ishida,et al.  Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes , 2010, Pharmaceutical Research.

[41]  M. Dellian,et al.  Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer , 2010, International journal of cancer.

[42]  G. Brix,et al.  Cationic lipid complexed camptothecin (EndoTAG®-2) improves antitumoral efficacy by tumor vascular targeting , 2007, Cancer biology & therapy.

[43]  P. Lin,et al.  Endothelial cell adhesion molecules and cancer progression. , 2007, Current medicinal chemistry.

[44]  J. Geng,et al.  P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[45]  K. Chou,et al.  P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. , 2004, Current medicinal chemistry.

[46]  M. Dellian,et al.  Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels , 2003, International journal of cancer.

[47]  M. Dellian,et al.  Protamine enhances uptake of cationic liposomes in angiogenic microvessels of solid tumours , 2004, Angiogenesis.